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Abstract
Background: Quercetin, one of the most widely distributed flavonoids in plants, has been demonstrated to reduce
hyperlipidaemia and atherosclerotic lesion formation. Reverse cholesterol transport (RCT) plays a crucial role in
exporting cholesterol from peripheral cells, which is one mechanism utilized in the prevention and treatment of
atherosclerosis. The aim of this study is to investigate whether quercetin reduces lipid accumulation by improving
RCT in vivo.
Methods: Apolipoprotein E-deficient mice fed a high-fat diet were used to investigate the effect of quercetin on
RCT by an isotope tracing method, and the underlying mechanisms were clarified by molecular techniques.
Results: These novel results demonstrated that quercetin significantly improved [3H]-cholesterol transfer from [3H]-
cholesterol-loaded macrophages to the plasma (approximately 34% increase), liver (30% increase), and bile (50% increase)
and finally to the feces (approximately 40% increase) for excretion in apolipoprotein E-deficient mice fed a high-fat diet.
Furthermore, quercetin markedly increased the cholesterol accepting ability of plasma and high-density lipoprotein (HDL)
and dramatically decreased the content of malondialdehyde in plasma and oxidized phosphocholine carried by HDL.
Therefore, the underlying mechanisms of quercetin in improving RCT may be partially due to the elevated cholesterol
accepting ability of HDL, the increased expression levels of proteins related to RCT, such as ATP-binding cassettes (ABC) A1
and G1, and the improved antioxidant activity of HDL.
Conclusion: Quercetin accelerates RCT in an atherosclerosis model, which is helpful in clarifying the lipid-lowering
effect of quercetin.
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Background
The cardiovascular protective effects of the natural product
quercetin may be partially attributed to its antioxidant [1]
and anti-inflammatory [2] properties. It is noteworthy that
recent studies indicated that quercetin decreases hyperlip-
idaemia in different high-fat diet fed animals [3–6].
Hyperlipidaemia is one of the major risk factors for
the onset and progression of atherosclerosis, and reverse
cholesterol transport (RCT) is believed to facilitate it by
transporting excess cholesterol from peripheral tissues
to the liver and small intestine for excretion [7]. Consid-
ering its lipid-lowering effects, quercetin may play an
important role in the development of atherosclerosis by
regulating RCT. An in vitro study has indicated that
quercetin may activate ATP-binding cassette (ABC) A1
by up-regulating peroxisome proliferator-activated recep-
tor γ (PPAR-γ) and liver X receptor α (LXR-α) [8], while
other research showed that quercetin enhances ABCA1
expression through a p38-dependent pathway in macro-
phages [9]. Our previous data indicated that quercetin
improves the expression of RCT-related proteins in
apolipoprotein E-deficient (apoE−/−) mice [3]. However,
there is little known about the in vivo biological effects
* Correspondence: shucunqin@hotmail.com; SD-GUO@hotmail.com
†Equal contributors
1Key Laboratory of Atherosclerosis in Universities of Shandong Province,
Institute of Atherosclerosis, Taishan Medical University, 2# Yingsheng East
Road, Taian, Shandong Province 271000, China
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Cui et al. Lipids in Health and Disease  (2017) 16:9 
DOI 10.1186/s12944-016-0393-2
and mechanisms of quercetin on RCT. Based on the
previous reports, we suppose that the lipid-lowering ef-
fect of quercetin may be partially attributed to its
stimulation of RCT.
The aim of this study is to investigate whether quercetin
improves RCT in an atherosclerosis model of “apoE−/−




Raw 264.7 macrophages were purchased from Shanghai
BoYao Biological Technology Co., Ltd. (Shanghai, China).
Quercetin was a Sigma-Aldrich product. Dulbecco’s
modified Eagle’s medium (DMEM) and feotal bovine
serum (FBS) were from Gibco (BRL, Gaithersburg, MD,
USA). Complete protease inhibitor cocktail tablets were
purchased from Roche (Schweiz, Germany). RIPA lysis
buffer was a product of Solarbio (Beijing, China). Rabbit
polyclonal antibody against ABCG1, mouse monoclonal
antibody against ABCA1 and rabbit monoclonal antibody
against scavenger receptor B type 1 (SR-B1) were from
Abcam (Cambridge, MA, USA). Enhanced chemilu-
minescence (ECL) kits were purchased from Thermo





3-phosphocholine (PGPC) and 1-hexadecyl-2-azelaoyl-
sn-glycero-3-phosphocholine [(COOH)PC] were purchased
from Avanti Polar Lipids Inc. (Alabaster, AL, USA). An
assay kit for malondialdehyde (MDA) was the product
of Nanjing Jiancheng Bioengineering Institute (Nanjing,
Jiangsu, China). All reagents used in this study were of
analytical grade.
Animals and grouping
Twenty-four apoE−/− mice with a C57BL/6 genetic back-
ground (male, 20 ± 2 g) were purchased from Beijing HFK
Bioscience Co., Ltd. (license number: SCXK2009-0004).
All experiments were approved by the Laboratory Animal
Ethical Committee of Taishan Medical University and
followed the NIH guidelines for the care and use of ani-
mals. Mice were fed a high-fat diet (15% fat and 1.25%
cholesterol). After a one-week adaptive phase, the mice
were randomly divided into 2 groups, namely, the
CMCNa group (n = 12, 0.5% carboxymethyl cellulose
sodium by gavage) and the quercetin group (n = 12,
12.5 mg/kg/d quercetin in 0.5% CMCNa by gavage).
The dosage of quercetin was determined in accordance
with a previous study [3].
Preparation of high density lipoprotein (HDL)
After 8 weeks of treatment, 6 animals from each group
were randomly chosen and blood was sampled from the
retro-orbital sinus after 6 h fasting. Plasma was prepared
by the centrifugation of the fresh blood at 1100 × g for
15 min at 4 °C. Lipoproteins were prepared using se-
quential ultracentrifugation according to the method de-
scribed in a previous publication [10]. Briefly, the plasma
density was adjusted to 1.063 g/mL for ultracentrifuga-
tion at 10 °C (70,000 rpm for 24 h). The upper layer of
non-HDL was removed, and the rest was adjusted to
1.21 g/mL density for ultracentrifugation at 70,000 rpm
for another 48 h to obtain HDL in the upper layer. The
protein content was determined by the Bradford method.
Isolated plasma and HDL were kept under nitrogen gas at
4 °C for in vitro cholesterol efflux assays and liquid
chromatography-tandem mass spectrometry (LC-MS/MS)
analysis.
Preparation of [3H]-cholesterol-loaded macrophages
[3H]-cholesterol (5 μCi/mL) and oxidized low-density
lipoprotein (LDL, 100 μg/mL) were mixed and pre-
incubated at 37 °C for 30 min. Raw 264.7 macrophages
were cultured in DMEM medium (10% FBS) supple-
mented with the above mixture. The cells were harvested
after 48 h incubation and intraperitoneally injected into
mice (6.0 × 105 cells containing 4.0 × 105 counts/min in
0.5 mL of DMEM per mouse) [11].
RCT assay in vivo
After 8 weeks of treatment, the other 6 mice in each
group were used for isotope tracing study. After the in-
jection of [3H]-cholesterol-loaded macrophages, blood
was sampled from the retro-orbital sinus at the time
points of 0, 6, 12 and 24 h, 100 μL per mouse each time.
Faeces were collected every 24 h. Blood was sampled at
48 h after the injection, as described above. Animals
were killed, and the liver and bile were collected.
Liver (0.3 g) and faeces were homogenized in a hexane/
isopropanol (3:2, v/v) solution, and the mixtures were
placed on a shaker for 12 h at room temperature. Then,
the mixture was centrifuged at 5000 × g for 15 min, and
the supernatant was kept for measurement. Prepared sam-
ples were transferred into 5.0 mL scintillation vials, and
4.0 mL of HIONIC FLUOR™ complete LSC-cocktail (Per-
KinElmer, Inc., Waltham, MA, USA) was then added and
mixed well. The scintillation vials were counted on a SN-
6930B type liquid scintillation counter (BECKMAN, USA).
The results were expressed as a percentage of injected
[3H]-cholesterol or directly by counts per minute (CPM).
The cholesterol efflux assay in vitro
This experiment was performed as suggested by Low et
al. with some modifications [12]. Briefly, Raw 264.7
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macrophages were plated into 24-well plates at a final
density of 1 × 105 cells per well. Six hours later, the culture
medium was discarded and cells were gently washed with
PBS 3 times. Then, 600 μL of DMEM containing 1% FBS
and 1 μCi/mL [3H]-cholesterol was added to each well
and incubated for another 24 h. After the incubation, the
medium containing [3H]-cholesterol was removed, and
the cells were gently washed with PBS 3 times. Cells were
treated with 500 μL of DMEM containing 1% FBS in the
presence or absence of quercetin for 4 h, and 100 μL of
HDL (final concentration of 20 μg/mL) or 10 μL of plasma
was then added and incubated for another 6 h. The cul-
ture medium was collected in 1.5-mL microfuge tubes
and centrifuged at 14,000 rpm for 10 min at room
temperature to remove cellular debris. Cells in the well
were treated with 1 mL of hexane/isopropanol (3:2, v/v)
for 30 min at room temperature. The extract was trans-
ferred into 1.5-mL microfuge tubes and centrifuged as
described above. Next, 200 μL of medium or cell extract
was used for measuring [3H]-cholesterol, as described
above.
Protein isolation, electrophoresis, and western blotting
Total proteins from the cells were extracted and prepared
for western blotting, as explained in detail in a previous
publication [13].
Lipid extraction
Lipids from HDL were extracted according to the method
of Bligh and Dyer with some modifications [14]. (1) For
100.0 μg of HDL, 1.0 mL of water and 3.75 mL of 1:2 (v/v)
CHCl2: MeOH were added and vortexed for at least
5 min; (2) 1.25 mL of CHCl2 was added and vortexed well;
(3) 1.25 mL of water was added and vortexed well. (4) The
mixture was centrifuged at 1500 rpm for 10 min, and the
bottom organic phase was recovered and dried under ni-
trogen gas. (5) The dryness was dissolved in 0.5 mL of
mobile phase and centrifuged at 20,000 rpm for 20 min,
and the upper phase was used directly for LC-MS/MS
analysis.
Measurement of oxidized lipids by LC-MS/MS
The composition of LC-MS/MS and the column used
were the same as a previous publication [13]. The mobile
phase A was composed of 2.0 mM ammonium acetate
and 0.1% acetic acid in methanol, and mobile phase B was
composed of 2.0 mM ammonium acetate and 0.1% acetic
acid in water. The flow rate was 0.4 mL/min with the
following elution gradient: 0.01-25 min: 5% B-1% B;
25–26 min: 1% B-5% B; 26–30 min: 5% B. Quantification
was performed with Analyst Software 1.6 (AB SCIEX,
USA).
Data analysis
All of the bioassay results were expressed as the mean ±
standard deviation (SD) for at least three independent
experiments. Statistical analysis was performed using one-
way analysis of variance (ANOVA) followed by Tukey’s
test. Differences were considered to be significant at a
P < 0.05.
Results
Quercetin improves RCT in apoE−/− mice fed a high-fat diet
Compared to CMCNa-treated mice, quercetin adminis-
tration increased the transfer rate of [3H]-cholesterol
from the injected macrophages to the plasma, and this
was significant at the 6, 12 and 24 h time points (Fig. 1a).
More importantly, compared to the CMCNa-treated
mice, [3H]-cholesterol transported to the liver and bile
for excretion was remarkably increased in the quercetin-
treated mice, with 30.3% and 50.1% increases, respect-
ively (Fig. 1b and c). As a consequence, [3H]-cholesterol
excreted in the faeces was significantly elevated at 0–24
(35.7% increase) and 24–48 h (44.4% increase) in the
quercetin-treated mice compared to the controls (Fig. 1d).
Plasma and HDL from the mice were used for further
investigation in vitro. The results showed that the [3H]-
cholesterol efflux from macrophages to plasma (31.8%
increase) and HDL (22.1% increase) of the quercetin-
treated mice was dramatically increased compared to
that of controls (Fig. 1e and f ). MDA, a lipid peroxida-
tion product, was significantly reduced in the plasma of
the quercetin-treated mice compared to the CMCNa-
treated mice (Fig. 1g); lipid oxidized phosphocholines,
including PGPC, POVPC, (ALDO)PC, PAZPC and
(COOH)PC, were significantly decreased in HDL parti-
cles from quercetin-treated mice compared with those
of the controls (Fig. 1h).
Quercetin improves cholesterol efflux and ABCA1 and
ABCG1 expression in vitro
Quercetin improved [3H]-cholesterol efflux in a con-
centration-dependent manner within a concentration
range of 0 to 10 μM (Fig. 2a). Several major proteins re-
lated to cholesterol efflux were measured by western
blotting, as shown in Fig. 2b-d. Quercetin significantly
improved the protein expression of ABCA1 and ABCG1
at a concentration of 2.5 μM. In addition, the protein ex-
pression of ABCG1 was regulated in a concentration-
dependent manner (Fig. 2e).
Discussion
RCT is a protective mechanism involved in the develop-
ment of atherosclerosis. This study reveals that quercetin
significantly improves RCT in vivo for the first time
using [3H]-cholesterol, with the underlying mechanisms
possibly attributed to the increased cholesterol accepting
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capacity of HDL, the elevated protein expression levels
of ABCA1 and ABCG1, and the reduction of oxidation.
These results are helpful in clarifying the lipid-lowering
effect of quercetin as previously reported [3–6].
High-fat diet induced hyperlipidaemia promotes the
entry and retention of abnormal LDL within the arterial
wall. The ingestion of the accumulated abnormal LDL
by macrophages in the sub-endothelial space of vessels
results in foam cell formation, a pathological step of
early atherosclerosis. RCT could transport excess choles-
terol from peripheral cells, especially macrophages, to
the liver and small intestine for excretion.
In a previous study, we demonstrated that quercetin
reduces hyperlipidaemia and lipid accumulation in the
liver and aorta in the apoE−/− mice fed a high-fat diet [3].
It is interesting to investigate whether the lipid-lowering
Fig. 1 Quercetin improves reverse cholesterol transport in apoE−/− mice (n = 6). a Quercetin increases the transfer rate of [3H]-cholesterol from injected
foam macrophages to the plasma of apoE−/− mice; (b) [3H]-cholesterol in the liver of the apoE−/− mice after 48 h injection; (c) [3H]-cholesterol in the
bile of the apoE−/− mice after 48 h injection; (d) [3H]-cholesterol in the faeces of the apoE−/− mice; (e) in vitro [3H]-cholesterol efflux assay using plasma
as acceptor; (f) in vitro [3H]-cholesterol efflux assay using HDL particles as acceptor; (g) levels of plasma MDA as measured by assay kit; (h) levels of
oxidized phosphocholines as measured by LC-MS/MS. CMCNa: carboxymethyl cellulose sodium. Data are expressed as the mean ± SD. & p < 0.05 vs
CMCNa group; && p < 0.01 vs CMCNa group
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effect of quercetin is related to RCT. The results of this
study showed that quercetin significantly improved RCT
in vivo for the first time (Fig. 1). It is acknowledged that
apolipoprotein A1 (apoA1) and HDL are major acceptors
of peripheral cholesterol. Previously, quercetin was indi-
cated to have no effect on the content of apoA1 [3], which
is beneficial to RCT. However, the results of this study
showed that quercetin treatment significantly improved
the [3H]-cholesterol accepting capacity of the plasma from
apoE−/− mice (Fig. 1e), and the increased ability may be
partially attributed to the increased cholesterol accepting
ability of HDL (Fig. 1f). In addition, the oxidation of HDL
and apoA1 were found to reduce their cholesterol accept-
ing ability [15]. The results of this study showed that
plasma MDA and oxidized phosphocholines in HDL
(Fig. 1g and h) were significantly decreased in quercetin-
treated mice, and our previous data indicated that quer-
cetin could improve the antioxidant ability of apoE−/− mice
fed a high-fat diet [3]. Therefore, the antioxidant activity of
quercetin may also contribute to the improved cholesterol
accepting ability of HDL and apoA1.
It is well known that ABCA1 and ABCG1 mediate chol-
esterol efflux to apoA1 and HDL, respectively. The present
study indicated that quercetin increased [3H]-cholesterol
efflux from macrophages to media in a concentration-
dependent manner in vitro. Therefore, the elevated
[3H]-cholesterol transfer rate from [3H]-cholesterol-
loaded macrophage to the plasma in quercetin-treated
apoE−/− mice may be due to the increased protein ex-
pression of ABCA1 and ABCG1, as shown in Fig. 2,
and these results are consistent with a previous in vivo
study [3]. These results showing that quercetin can sig-
nificantly improve ABCA1 expression are consistent with
previous publications [8, 9]. It has been demonstrated that
quercetin may activate ABCA1 by up-regulating PPAR-γ
and LXR-α [8] or through stimulating the phosphorylation
Fig. 2 Quercetin improves cholesterol efflux and the protein expression of ABCA1 and ABCG1 in Raw264.7 macrophages (n = 3). a Quercetin improves
[3H]-cholesterol efflux in a concentration-dependent manner; (b) protein expression of SR-B1 and densitometric quantification; (c) protein expression of
ABCA1 and densitometric quantification; (d) protein expression of ABCG1 and densitometric quantification; (e) quercetin improves the protein
expression of ABCG1 in a concentration-dependent manner. Data are expressed as the mean ± SD. & p < 0.05 vs blank group; && p < 0.01 vs
blank group
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of p38 via an activation of the transforming growth factor
β-activated kinase 1 and mitogen-activated kinase 3/6 [9].
In the present study, we report for the first time that quer-
cetin could improve the protein expression of ABCG1 in a
concentration-dependent manner in vitro, which is con-
sistent with an in vivo report [3]. SR-B1 plays a significant
role in the transfer of cholesterol to mature HDL. How-
ever, there were no significant changes in SR-B1 in quer-
cetin–treated mice. A previous study from our group also
showed that the ethanolic extract of propolis (quercetin is
one the major effective components of propolis) has no
significant influence on the protein expression of SR-B1
both in vitro and in vivo [11]. However, the effect of flavo-
noids on SR-B1 protein expression remains unresolved.
In mice, cholesterol can be delivered to liver directly by
SR-B1 and indirectly by the LDL receptor after free choles-
terol has been transformed to cholesterol esters by the ac-
tion of lecithin cholesterol acyltransferase. In other words,
cholesterol esters of very low density lipoprotein and LDL
could be removed by the liver through the LDL receptor,
which is beneficial to RCT. In a previous study, quercetin
was demonstrated to increase the protein expression of the
LDL receptor in vivo [3], which could partially explain the
elevated liver [3H]-cholesterol in apoE−/− mice in the
present study. Therefore, quercetin may elevate the liver
uptake of [3H]-cholesterol mainly by up-regulating the
LDL receptor pathway in apoE−/− mice. Furthermore,
ABCG5 is an important mediator involved in the secretion
of cholesterol from the liver and small intestines. Quercetin
treatment up-regulates the expression of ABCG5 in liver
and small intestine [3], which may contribute to the in-
crease of [3H]-cholesterol in the bile and subsequently in
the faeces of apoE−/− mice. As one of the widely-
distributed flavonoids in plants, quercetin is also one of the
major components of natural nutraceuticals. Therefore,
quercetin may partially contribute to the lipid-lowering ef-
fect of nutraceuticals, as has been well documented by
Scicchitano et al. [16].
Plasma cholesteryl ester transfer protein (CETP) facilitates
the transfer of cholesteryl esters from HDL to LDL and
VLDL and is a key protein in RCT. However, mice naturally
lack CETP. Furthermore, mouse plasma is characterized as
HDL-C dominant, while human plasma is non-HDL-C
dominant. Therefore, the major limitation of the present
study is that the results may not reflect what is occurring in
humans. Thus, our next plan is to verify the effect of quer-
cetin in CETP transgenic mice, whose lipid profile is closer
to humans than apoE−/− mice. Another limitation of this
study is that the pathways are not further investigated with
the help of interfering means such as siRNA.
Conclusions
Quercetin improves RCT by up-regulating related pro-
tein expression levels, such as ABCA1 and ABCG1, and
also by elevating the cholesterol accepting ability of
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